|
1
|
Chao J, Song L, Zhang H, et al: Effects of
comprehensive intervention on health-related quality of life in
patients with chronic hepatitis B in China. BMC Health Serv Res.
13:3862013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang X, Zhang M, Lai Q, et al: Restored
circulating invariant NKT cells are associated with viral control
in patients with chronic hepatitis B. PLoS One. 6:e288712011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liaw YF: Impact of therapy on the outcome
of chronic hepatitis B. Liver Int. 33(Suppl 1): 111–115. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lam YF, Yuen MF, Seto WK and Lai CL:
Current antiviral therapy of chronic hepatitis B: efficacy and
safety. Curr Hepat Rep. 10:235–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Webster GJ, Reignat S, Brown D, et al:
Longitudinal analysis of CD8+ T cells specific for structural and
nonstructural hepatitis B virus proteins in patients with chronic
hepatitis B: implications for immunotherapy. J Virol. 78:5707–5719.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ribeiro RM, Germanidis G, Powers KA, et
al: Hepatitis B virus kinetics under antiviral therapy sheds light
on differences in hepatitis B e antigen positive and negative
infections. J Infect Dis. 202:1309–1318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carey I, D’Antiga L, Bansal S, et al:
Immune and viral profile from tolerance to hepatitis B surface
antigen clearance: a longitudinal study of vertically hepatitis B
virus-infected children on combined therapy. J Virol. 85:2416–2428.
2011. View Article : Google Scholar :
|
|
8
|
Liang M, Ma S, Hu X, et al: Cellular
immune responses in patients with hepatitis B surface antigen
seroclearance induced by antiviral therapy. Virol J. 8:692011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boni C, Fisicaro P, Valdatta C, et al:
Characterization of hepatitis B virus (HBV)-specific T-cell
dysfunction in chronic HBV infection. J Virol. 81:4215–4225. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boni C, Laccabue D, Lampertico P, et al:
Restored function of HBV-specific T cells after long-term effective
therapy with nucleos(t)ide analogues. Gastroenterology.
143:963–973. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang Y, Ma Z, Xin G, et al: Th1 and Th2
immune response in chronic hepatitis B patients during a long-term
treatment with adefovir dipivoxil. Mediators Inflamm.
2010:1430262010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rico MA, Quiroga JA, Subirá D, et al:
Hepatitis B virus-specific T-cell proliferation and cytokine
secretion in chronic hepatitis B e antibody-positive patients
treated with ribavirin and interferon alpha. Hepatology.
33:295–300. 2001. View Article : Google Scholar
|
|
13
|
Tsai SL, Sheen IS, Chien RN, et al:
Activation of Th1 immunity is a common immune mechanism for the
successful treatment of hepatitis B and C: tetramer assay and
therapeutic implications. J Biomed Sci. 10:120–135. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Li X, Ye B, et al: Effect of
telbivudine therapy on the cellular immune response in chronic
hepatitis B. Antiviral Res. 91:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janssen EM, Lemmens EE, Wolfe T, et al:
CD4+ T cells are required for secondary expansion and memory in
CD8+ T lymphocytes. Nature. 421:852–856. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Chen Y, Ma Z, et al: Effect of
regulatory T cells and adherent cells on the expansion of
HBcAg-specific CD8+ T cells in patients with chronic hepatitis B
virus infection. Cell Immunol. 264:42–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stoop JN, van der Molen RG, Kuipers EJ, et
al: Inhibition of viral replication reduces regulatory T cells and
enhances the antiviral immune response in chronic hepatitis B.
Virology. 361:141–148. 2007. View Article : Google Scholar
|
|
18
|
Wherry EJ, Blattman JN and Ahmed R: Low
CD8 T-cell proliferative potential and high viral load limit the
effectiveness of therapeutic vaccination. J Virol. 79:8960–8968.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thimme R, Wieland S, Steiger C, et al:
CD8(+) T cells mediate viral clearance and disease pathogenesis
during acute hepatitis B virus infection. J Virol. 77:68–76. 2003.
View Article : Google Scholar :
|
|
20
|
Maini MK, Boni C, Lee CK, et al: The role
of virus-specific CD8(+) cells in liver damage and viral control
during persistent hepatitis B virus infection. J Exp Med.
191:1269–1280. 2000. View Article : Google Scholar : PubMed/NCBI
|
